Amneal Pharmaceuticals Inc
NYSE:AMRX
Amneal Pharmaceuticals Inc
NYSE:AMRX
Price:
6.765 USD
8.94%
Market Closed
Updated:
May 3, 2024
Amneal Pharmaceuticals Inc
Revenue
|
Amneal Pharmaceuticals Inc
Revenue Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Amneal Pharmaceuticals Inc
NYSE:AMRX
|
Revenue
$2.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$81.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$58.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$34.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
Amneal Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Amneal Pharmaceuticals Inc
Amneal Pharmaceuticals Inc
Not Available
Breakdown by Segments
Amneal Pharmaceuticals Inc
Amneal Pharmaceuticals Inc
|
Total Revenue:
2.4B
USD
|
|
Generics:
1.5B
USD
|
|
Avkare:
531.7m
USD
|
|
Specialty:
390.5m
USD
|
See Also
What is Amneal Pharmaceuticals Inc's Revenue?
Revenue
2.4B
USD
2.4B
USD
Based on the financial report for Dec 31, 2023, Amneal Pharmaceuticals Inc's Revenue amounts to 2.4B USD.
What is Amneal Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
17%
17%
Over the last year, the Revenue growth was 8%. The average annual Revenue growth rates for Amneal Pharmaceuticals Inc have been 6% over the past three years , 8% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet
